title: Evidence for autocrine growth stimulation of cultured colon tumor cells by a gastrin/cholecystokinin-like peptide.
abstract: The peptide gastrin has been shown to have growth stimulatory effects on normal as well as malignant gastrointestinal tissue. In this study, we have examined the possibility of autocrine growth-stimulation of cultured colon tumor cells by a gastrin-like peptide. The gastrin/CCK receptor antagonist dibutyryl cGMP inhibited the proliferation of two human colon carcinoma cell lines HCT 116 (EC50 = 1.3 mM) and CBS (EC50 = 2.5 mM) in a dose-dependent manner. Marked morphological changes were observed in HCT 116 cells after treatment with 1 mM dibutyryl cGMP. In receptor binding assays, dibutyryl cGMP competed with 125I-labeled gastrin for binding to HCT 116 cells (IC50 = 1.8 mM). Another derivative of cyclic GMP, 8-Bromo cGMP used as control due to its considerably weaker affinity for the gastrin/CCK receptor, did not compete with radiolabeled gastrin for binding to HCT 116 cells and had no effect on the morphology or proliferation in monolayer cultures of HCT 116 or CBS cells at concentrations up to 10 mM. Antigastrin/CCK antisera was also found to have dose-dependent cytostatic effects on HCT 116 and CBS cells adapted to growth in serum-free medium. The antiproliferative effect of the gastrin/CCK receptor antagonist and antigastrin/CCK antibodies suggested that a gastrin-like peptide secreted by these cells may promote growth. Radioimmunoassay of the conditioned medium of these two cell lines indicated the presence of a gastrin-like peptide (10-50 pg/10(6) cells/72 h). Northern analysis using an oligonucleotide DNA probe complementary to the nucleotide sequence coding the dodecapeptide carboxyl terminal of human gastrin showed three transcripts (0.7, 3.3, and 3.7 kb) that hybridized with the probe. These data provide, for the first time, evidence for an autocrine growth stimulatory role of a gastrin/CCK-like peptide in cultured colon tumor cells.
authors.affiliation: Bristol-Baylor Laboratory, Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77030.
authors.forename: N M
authors.initials: NM
authors.lastname: Hoosein
authors.forename: P A
authors.initials: PA
authors.lastname: Kiener
authors.forename: R C
authors.initials: RC
authors.lastname: Curry
authors.forename: M G
authors.initials: MG
authors.lastname: Brattain
mesh_terms: D015152:Blotting, Northern; D002460:Cell Line; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000473:pathology; D002766:Cholecystokinin / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D003110:Colonic Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000648:ultrastructure; D003995:Dibutyryl Cyclic GMP / Q000494:pharmacology; D005755:Gastrins / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D007106:Immune Sera / Q000276:immunology; D011863:Radioimmunoassay; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure
chemical_list: D005755:Gastrins; D007106:Immune Sera; D011949:Receptors, Cholecystokinin; D003995:Dibutyryl Cyclic GMP; D002766:Cholecystokinin